NCT06180733View on ClinicalTrials.gov

Neo-adjuvant Pembrolizumab as an Alternative Treatment for MMRd Uterine Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

December 1, 2023

Primary Completion Date

December 30, 2027

Study Completion Date

January 31, 2028

Conditions
Endometrial Cancer
Interventions
DRUG

Pembrolizumab Injection [Keytruda]

Pembrolizumab (Keytruda), 200mg IV Q3W for a total of 9 administrations per patient, prior to standard-of-care surgery. Patients will be monitored for response and possible progression using MRI and pipelle biopsies.

Trial Locations (1)

9700 RB

RECRUITING

University Medical Centre Groningen, Groningen

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University Medical Center Groningen

OTHER

NCT06180733 - Neo-adjuvant Pembrolizumab as an Alternative Treatment for MMRd Uterine Cancer | Biotech Hunter | Biotech Hunter